At the news
? BULLISHIMPACT 7/10 8-K filed Sep 15, 2026 at 07:06 ET
Rocket Pharmaceuticals announced FDA alignment on the path to complete the pivotal Phase 2 trial of RP-A501 for Danon disease. The FDA confirmed a 12-patient pivotal population at a recalibrated dose, with the first three patients already treated counting toward that total, and preserved 12-month co-primary endpoints intended to support potential accelerated approval. This removes a key regulatory overhang and provides a clear path to enrollment completion by mid-2027, a significant de-risking event for the program.
- FDA confirmed continued enrollment and dosing under the modified protocol at the recalibrated dose of 3.8 × 10^13 GC/kg.
- Pivotal study population set at 12 male patients; first three patients treated count toward this total, leaving nine to enroll.
- Rocket expects to complete dosing of remaining patients by mid-2027.
- Co-primary endpoints of myocardial LAMP2 protein expression and a 10% reduction from baseline in left ventricular mass index at 12 months are preserved to support potential accelerated approval.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access